Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial

Summary: Background: Synucleinopathies such as Parkinson ́s disease (PD), Dementia with Lewy bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of misfolded and aggregated α-synuclein. Small aggregates (oligomers) of α-synuclein have been shown to be the most relevant ne...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Johannes Levin, Nand Sing, Sue Melbourne, Amber Morgan, Carla Mariner, Maria Grazia Spillantini, Michal Wegrzynowicz, Jeffrey W. Dalley, Simon Langer, Sergey Ryazanov, Andrei Leonov, Christian Griesinger, Felix Schmidt, Daniel Weckbecker, Kai Prager, Torsten Matthias, Armin Giese
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-06-01
coleção:	EBioMedicine
Assuntos:	Multiple system atrophy Parkinson disease α-synuclein Protein aggregation Anle138b Disease modification
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2352396422002055
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!